|
2009.12
|
Prochymal/Osiris Therapeutics, Inc., USA
|
Mesenchymal stem cells from human allogeneic bone marrow
|
Graft versus host disease (GVHD) and Crohn’s disease
|
American Food and Drug Administration (FDA)
|
|
2010.07
|
MPC/Mesoblast
|
Autologous mesenchymal precursor cells
|
Bone reconstruction
|
Production permit of Therapeutic Goods Administration (TGA) in Australia
|
|
2011.07
|
Hearticellgram-AMI/FCB-Pharmicell
|
Autologous bone marrow mesenchymal stem cells
|
Acute myocardial infarction
|
Food and Drug Administration in South Korea
|
|
2011.11
|
Hemacord/New York Blood Center
|
Cord blood hematopoietic progenitor cells
|
Hereditary or acquired hematopoietic disease
|
Biological License of American Food and Drug Administration (FDA)
|
|
2011.11
|
MultiStem/Athersys Inc., USA
|
Allogeneic bone marrow stem cell
|
Type I mucopolysaccharidosis
|
American Food and Drug Administration (FDA)
|
|
2012.01
|
Cartistem/Medi-post
|
Mesenchymal stem cells from the cord blood
|
Degenerative arthritis and cartilage damage in the knee joint
|
Food and Drug Administration in South Korea
|
|
2012.01
|
Cuepistem/Anterogen
|
Mesenchymal stem cells from autologous fat
|
Crohn’s disease complicating anal fistula
|
Food and Drug Administration in South Korea
|
